Solvent system optimization for controlled LNP self-assembly, particle size tuning, encapsulation efficiency improvement, and batch-to-batch process consistency.
The solvent system is one of the most influential process variables in lipid nanoparticle (LNP) formation. During nanoprecipitation, lipids dissolved in the organic phase rapidly encounter an aqueous phase containing nucleic acids or other payloads, triggering polarity change, lipid aggregation, ionizable lipid-cargo association, and particle self-assembly within a very short mixing window. Small variations in ethanol fraction, aqueous-to-organic ratio, buffer composition, dilution kinetics, or solvent removal strategy can shift particle size, PDI, encapsulation efficiency, and post-processing stability. BOC Sciences provides LNP solvent system optimization services for formulation and production teams seeking a rational process window that connects early formulation screening with reproducible LNP preparation. Our approach integrates solvent ratio mapping, aqueous phase design, microfluidic mixing assessment, ethanol dilution control, buffer exchange optimization, and analytical feedback to help clients build LNP processes with predictable assembly behavior and robust batch performance.
We provide a systematic optimization framework for the organic phase, aqueous phase, ethanol content, phase ratio, mixing pathway, and solvent removal conditions used in LNP preparation. Each study is designed around the client's target payload, lipid composition, process format, and desired LNP quality attributes.
The organic phase determines how lipids are solubilized before mixing and how quickly they become supersaturated during ethanol dilution. We optimize lipid concentration, ethanol strength, lipid stock compatibility, and optional co-solvent strategies when formulation solubility is challenging.
The aqueous phase affects ionizable lipid protonation, nucleic acid complexation, osmotic balance, and early particle stabilization. We help identify buffer conditions that support efficient cargo capture while minimizing aggregation after mixing.
Ethanol is not only a lipid solvent; it also controls the rate of polarity change that drives LNP nucleation and growth. We optimize the ethanol fraction at formation and during post-mixing dilution to stabilize the desired particle size distribution.
The aqueous-to-organic ratio directly influences lipid dilution rate, supersaturation, nanoparticle nucleation density, and final particle size. We establish ratio-response profiles to define a practical formation window.
LNPs that appear acceptable immediately after formation may destabilize during ethanol removal, diafiltration, concentration, or final buffer exchange. We optimize post-formation conditions to preserve the assembled LNP structure.
A robust LNP process must tolerate small operational changes without producing unacceptable variation. We investigate how solvent-related variables interact with mixing time, total flow rate, lipid concentration, and batch scale.
Effective solvent optimization requires more than changing ethanol percentage alone. BOC Sciences combines formulation science, process engineering, and analytical characterization to determine how the solvent environment controls LNP assembly from the first mixing event through final buffer exchange.
Connect formulation design with production-ready process variables through systematic solvent ratio, buffer, mixing, and solvent removal optimization.
LNP solvent requirements vary significantly with cargo type, lipid chemistry, target particle size, and process format. We customize the optimization plan according to the formulation objective and the manufacturing pathway that the client intends to use.
| Project Context | How Solvent System Optimization Supports the Project |
|---|---|
| Lipid Nanoparticle Formulation | Establishes compatible organic and aqueous phase conditions for lipid solubilization, rapid self-assembly, particle size control, and early formulation screening. |
| Lipid Nanoparticles for mRNA Delivery | Optimizes acidic buffer conditions, ethanol dilution, aqueous-to-organic ratio, and RNA-lipid association to improve mRNA encapsulation and reduce particle heterogeneity. |
| Lipid Nanoparticles for siRNA Delivery | Adjusts aqueous phase ionic strength, solvent ratio, and post-mixing dilution to support efficient oligonucleotide loading while maintaining small and uniform LNPs. |
| Lipid Nanoparticles for Small Molecule Delivery | Evaluates solubility-driven organic phase strategies and solvent removal conditions for hydrophobic or amphiphilic small molecules that may partition into lipid domains. |
| LNP Process Optimization | Converts solvent observations into process parameters such as FRR, TFR, dilution factor, hold time, and buffer exchange sequence for reproducible batch preparation. |
| LNP Encapsulation Efficiency Optimization | Links solvent ratio and aqueous phase chemistry with cargo accessibility assays to identify conditions that improve encapsulation without increasing particle instability. |
| Lipid Nanoparticle Manufacturing | Supports process transfer by defining solvent conditions that remain stable during larger-volume mixing, concentration, diafiltration, and final formulation adjustment. |
| LNP Critical Quality Attributes & QC Testing | Uses size, PDI, zeta potential, encapsulation efficiency, residual solvent signal, and stability readouts to compare solvent system candidates objectively. |
Many LNP performance issues originate from the solvent environment rather than lipid molar ratio alone. We help clients identify and correct solvent-driven failure modes during formulation and production development.
✔ Broad Particle Size Distribution
A slow or uneven ethanol dilution front can produce excessive particle growth and a broad PDI. We screen phase ratios and mixing conditions to tighten the self-assembly window.
✔ Low Encapsulation Despite Suitable Lipid Ratios
Poor aqueous phase pH, ionic strength, or ethanol fraction can weaken cargo-lipid association during the first seconds of formation. We tune buffer and solvent conditions to improve cargo capture.
✔ Size Drift After Solvent Removal
LNPs may grow during diafiltration or buffer exchange if ethanol is removed too abruptly. We optimize exchange rate, dilution sequence, and concentration pathway to preserve particle structure.
✔ Batch-to-Batch Inconsistency
Small changes in solvent ratio, injection timing, or hold time can shift size and EE%. We identify robust operating ranges that reduce sensitivity to normal process variation.
✔ Lipid Precipitation or Channel Clogging
High lipid concentration, inadequate organic phase strength, or viscosity mismatch may cause precipitation before complete mixing. We modify solvent strength and lipid stock conditions to improve process continuity.
✔ Poor Transfer from Screening to Production
A solvent window that works in small-volume screening may fail during larger-scale processing. We evaluate ratio, flow, dilution, and exchange variables together to support process scalability.
We review lipid composition, cargo type, target particle size, intended preparation method, current solvent ratio, buffer system, and any observed issues such as low EE%, aggregation, or size drift.
We design a solvent optimization matrix covering organic phase strength, aqueous buffer condition, aqueous-to-organic ratio, ethanol dilution strategy, and mixing parameters, then prepare comparative LNP batches under controlled conditions.
Each condition is assessed for particle size, PDI, zeta potential, encapsulation efficiency, recovery, residual ethanol signal, and short-term colloidal stability to determine which solvent variables drive performance.
We provide a practical solvent system recommendation, including preferred phase ratio, buffer condition, dilution sequence, solvent removal approach, and analytical checkpoints for future batch monitoring.
Challenge: A formulation team preparing mRNA-loaded LNPs by microfluidic mixing observed variable particle sizes between 95 and 145 nm and inconsistent encapsulation efficiency between 68% and 78%. The lipid molar ratio had already been optimized, but the client still saw a wider PDI after repeating the same method on different preparation days.
Diagnosis: BOC Sciences reviewed the formation process and found that the aqueous-to-organic ratio and post-mixing dilution timing were creating different ethanol exposure histories. The client used an acidic aqueous buffer for mRNA complexation, but the final ethanol fraction after mixing remained high for several minutes before dilution, allowing continued particle rearrangement and size growth.
Solution: We designed a solvent matrix comparing aqueous-to-organic ratios of 2:1, 3:1, and 4:1, with total flow rate held constant to isolate the phase ratio effect. For each ratio, we tested immediate dilution, 2-minute hold, and staged dilution into the final buffer. DLS and RiboGreen-based encapsulation readouts showed that the 3:1 ratio combined with immediate controlled dilution produced the strongest balance between lipid dilution rate and cargo capture. We then repeated the condition across three preparation runs and monitored size change after buffer exchange.
Result: The optimized solvent condition produced LNPs in the 78-86 nm range with PDI < 0.12 and encapsulation efficiency increasing from approximately 72% to above 90%. The client obtained a reproducible solvent window suitable for further formulation comparison without changing the lipid composition.
Challenge: A production-oriented group developing LNPs for a hydrophobic small molecule cargo achieved acceptable size immediately after mixing, but particles grew by more than 30 nm after solvent removal and buffer exchange. The formulation also showed visible haze after overnight storage at 4°C.
Diagnosis: The formulation relied on a high-strength ethanol stock to dissolve the hydrophobic cargo with the lipid mixture. During diafiltration, ethanol was removed rapidly, forcing the cargo to repartition within the lipid phase before the particle structure stabilized. This abrupt polarity shift triggered partial cargo-lipid rearrangement and particle association.
Solution: BOC Sciences compared three solvent removal pathways: direct diafiltration, stepwise dilution before diafiltration, and inline dilution followed by low-flux buffer exchange. We also screened two final buffer ionic strengths to reduce colloidal stress during concentration. The best-performing condition used a staged dilution step to lower ethanol exposure gradually before buffer exchange, followed by controlled concentration to the target lipid level.
Result: Particle size drift after solvent removal decreased from more than 30 nm to less than 8 nm, and the PDI remained below 0.15 after 48 hours at 4°C. The client selected the staged dilution and controlled diafiltration pathway as the preferred post-formation process for subsequent batch development.
Formulation-Process IntegrationWe evaluate solvent variables as part of the complete LNP formation pathway, connecting lipid solubility, aqueous phase chemistry, phase ratio, mixing, dilution, and buffer exchange.
Cargo-Specific Solvent DesignOur team adapts solvent screening for mRNA, siRNA, ASO, pDNA, peptides, proteins, and small molecules rather than applying a single ethanol ratio across all LNP projects.
Microfluidic and Batch Mixing ExperienceWe support solvent optimization in microfluidic, ethanol injection, and other controlled mixing formats, helping clients understand how solvent behavior changes with preparation method.
Analytical Decision SupportSize, PDI, zeta potential, encapsulation efficiency, residual solvent signal, and short-term stability are integrated into condition selection so that decisions are based on multiple readouts.
Scale-Aware OptimizationWe identify solvent conditions that are not only effective in small screening runs but also practical for larger-volume preparation, concentration, and buffer exchange.
LNP solvent system optimization focuses on the solvent conditions used during LNP preparation, especially the organic phase, aqueous phase, and their behavior during rapid mixing. For LNPs carrying mRNA, siRNA, plasmid DNA, or other nucleic acid payloads, the solvent system strongly influences lipid solubilization, ionizable lipid–cargo complexation, nucleation kinetics, particle growth, and batch-to-batch reproducibility. Key optimization parameters often include ethanol content, lipid concentration in the organic phase, aqueous phase acidity, solvent compatibility before mixing, solvent displacement rate, and microfluidic mixing behavior. The goal is to establish a controllable self-assembly environment that supports desirable particle size, low PDI, high encapsulation efficiency, and robust initial LNP structure.
During LNP preparation, lipids are typically dissolved in an organic solvent and rapidly mixed with an aqueous phase containing the cargo. The transition from a solvent-rich environment to an aqueous environment drives lipid self-assembly, so solvent diffusion, local concentration gradients, mixing speed, and solvent-to-water ratio all influence nucleation and particle growth. If the solvent system is not well matched to the lipid composition, LNPs may show oversized particles, broad size distribution, aggregation, or poor reproducibility. BOC Sciences can help evaluate ethanol fraction, lipid concentration, flow rate ratio, total flow rate, and mixing configuration to identify a solvent condition that supports consistent nanoscale particle formation.
Ethanol percentage is one of the most important variables in LNP solvent system optimization because it determines how well ionizable lipids, helper lipids, cholesterol, and PEG-lipids remain dissolved before mixing. It also affects how quickly lipids precipitate, reorganize, and assemble into nanoparticles once the organic and aqueous phases meet. Excessive ethanol content may alter local assembly kinetics and cargo complexation, while insufficient ethanol may reduce lipid solubility and cause pre-mixing instability or non-uniform lipid distribution. Optimization should therefore consider ethanol percentage together with lipid composition, nucleic acid type, N/P ratio, lipid concentration, and microfluidic parameters rather than treating ethanol as an isolated factor.
Yes. In LNP solvent system optimization, aqueous phase conditions before and during mixing can significantly influence nucleic acid encapsulation. Parameters such as pH, ionic strength, cargo concentration, and aqueous-to-organic phase ratio affect the protonation state of ionizable lipids and the strength of lipid–nucleic acid interactions during the earliest stage of particle formation. An unsuitable aqueous phase may lead to reduced encapsulation efficiency, increased free nucleic acid, wider particle size distribution, or less compact internal structure. For nucleic acid LNP projects, BOC Sciences can compare matched aqueous and organic solvent conditions to determine which combination improves self-assembly efficiency and supports stable particle formation during preparation.
An optimized LNP solvent system is identified through comparative formulation screening rather than a single endpoint measurement. Typical evaluation criteria include particle size, PDI, encapsulation efficiency, visible precipitation, aggregation tendency, repeatability across preparation runs, and structural robustness during subsequent solvent removal steps. For early-stage formulation development, multiple ethanol percentages, lipid concentrations, aqueous phase conditions, flow rate ratios, and mixing modes can be compared to reveal the most reliable preparation window. A strong solvent system is not only one that produces good results once, but one that remains relatively insensitive to small process variations and consistently supports the target LNP quality attributes.
